Effects of Fibrates in Kidney Disease

Jun, Min, Zhu, Bin, Tonelli, Marcello, Jardine, Meg J., Patel, Anushka, Neal, Bruce, Liyanage, Thaminda, Keech, Anthony, Cass, Alan, Perkovic, Vlado·2012·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2012.07.049

Cited by (189)

Items 101–189 of 189

  1. Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on High-Density Lipoprotein Cholesterol
    Mohammad Abdullah Al Zubair Naim, Keiichi Sumida, Elani Streja, Fridtjof Thomas, Robert Lowell Davis, Kamyar Kalantar‐Zadeh, Csaba Pal Kovesdy · 2026 · Drugs
  2. A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease
    Arezoo Rajabian, Alice Patricia McCloskey, Tannaz Jamialahmadi, Seyed Adel Moallem, Amirhossein Sahebkar · 2023 · Reviews in the Neurosciences
  3. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
    Haralampos J. Milionis · 2014 · Expert Opinion on Drug Safety
  4. Fibrates and Cardiorenal Outcomes
    Peter Andrew McCullough, Michael J. Di Loreto · 2012 · Journal of the American College of Cardiology
  5. Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia
    Toshinori Komatsu, Takashi Miura, Kensuke Joko, Daisuke Sunohara, Tomoaki Mochidome, Toshio Kasai, Uichi Ikeda · 2021 · Internal Medicine
  6. Use of fibrates is not associated with reduced risks of mortality or cardiovascular events among ESRD patients: A national cohort study
    Wen-Yu Ho, Chieh‐Li Yen, Cheng‐Chia Lee, Yi‐Ran Tu, Chao‐Yu Chen, Ching-Chung Hsiao, Pao‐Hsien Chu, Hsiang‐Hao Hsu, Ya-Chun Tian, Chih‐Hsiang Chang · 2022 · Frontiers in Cardiovascular Medicine
  7. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy
    Vasilios Gabriel Athyros, Κωνσταντίνος Τζιόμαλος, Asterios I. Karagiannis · 2015 · Expert Review of Cardiovascular Therapy
  8. Diabetic dyslipidemia and microvascular complications of diabetes
    David Karásek, H Vaverková · 2018 · Vnitřní lékařství
  9. The impact of antihypertensives on kidney disease
    Diego Francisco Márquez, Gema Ruiz‐Hurtado, Luis Miguel Ruilope · 2017 · F1000Research
  10. Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy
    V. Kratky, A. Valerianova, Z. Hruskova, V. Tesař, Jan Malík · 2024 · Current Atherosclerosis Reports
  11. The Association of Fibrate Use with Kidney Outcomes and Mortality
    Rina Takahashi, Jenny I. Shen, Diana Tran, Ibrahim Elali, Tiane Dai, Anuja Pradip Shah, Ramnath Dukkipati, Adnan M. Ismail, Keiichi Sumida, Fridtjof Thomas et al. · 2025 · Clinical Journal of the American Society of Nephrology
  12. Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia
    Chieh‐Li Yen, Pei‐Chun Fan, Cheng‐Chia Lee, Jia‐Jin Chen, Chao‐Yu Chen, Yi‐Ran Tu, Pao‐Hsien Chu, Ching-Chung Hsiao, Yung‐Chang Chen, Chih‐Hsiang Chang · 2024 · Frontiers in Endocrinology
  13. Selective peroxisome proliferator-activated receptor-α modulator improves hypertriglyceridemia and muscle quality in patients with chronic kidney disease: A retrospective observational study
    Yukari Mae, Tomoaki Takata, Sosuke Taniguchi, Yudai Fujino, Kana Kageyama, Hinako Hanada, Takuji Iyama, Takaaki Sugihara, Hajime Isomoto · 2024 · Clinical Nutrition ESPEN
  14. Advancing care in primary biliary cholangitis: emerging insights and novel therapies
    Vögelin, Marius, Kremer, Andreas E. · 2025 · Expert Opinion on Pharmacotherapy
  15. Lipid-Lowering Therapy in Women of Childbearing Age: a Review and Stepwise Clinical Approach
    Jelani Kayode Grant, Sarah C. Snow, Michelle D. Kelsey, Jennifer A. Rymer, Anna E. Schaffer, Manesh R. Patel, Robert W. McGarrah, Neha Jadeja Pagidipati, Nishant P. Shah · 2022 · Current Cardiology Reports
  16. Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study
    Yukino Katakura, Masashi Shimoda, Mana Ohnishi, Takashi Kusano, Kazunori Dan, Hayato Isobe, Ryo Wamata, Yuichiro Iwamoto, Yoshiro Fushimi, Junpei Sanada et al. · 2023 · Nutrition Metabolism and Cardiovascular Diseases
  17. Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis
    Shujie Zhang, Tingting Sun, Lina Song · 2025 · European journal of medical research
  18. Guías de práctica clínica de manejo de la dislipemia en diabéticos y otros grupos de riesgo
    Marta Fanlo‐Maresma, Xavier Pintó · 2015 · Revista Española de Cardiología Suplementos
  19. Can Concurrent Fibrate Use Reduce Cardiovascular Risks among Moderate Chronic Kidney Disease Patients Undergoing Statin Therapy? A Cohort Study
    Li-Yi Ma, Pei‐Chun Fan, Chao‐Yu Chen, Yi‐Ran Tu, Ching-Chung Hsiao, Chieh‐Li Yen, Chih‐Hsiang Chang · 2023 · Journal of Clinical Medicine
  20. The prognostic value of remnant cholesterol to adverse renal outcomes in patients with type 2 diabetes
    Pan Yu, Qiongjing Yuan, Huang Ling, Lijian Tao, Zhangzhe Peng, Jiaxi Pu · 2025 · Diabetology & Metabolic Syndrome
  21. Diseases of Renal Microcirculation: Diabetic Nephropathy
    Ineke J. Riphagen, Hiddo J.L. Heerspink, Rijk O. B. Gans, Sandrine Gaillard · 2014 · Springer eBooks
  22. Lipid-lowering agents in chronic kidney disease: do fibrates have a role?
    Yuli Huang, Yunzhao Hu · 2013 · Nature Reviews Cardiology
  23. Cardiovascular Disease
    Jacqueline M. Lucey, Amber E. King, Drayton A. Hammond, Branden D. Nemecek · 2019 · ASHP eBooks
  24. Diabetic Nephropathy
    Peter R Rossing, Allan Flyvbjerg · 2024 · Wiley eBooks
  25. Drug-induced rise in serum creatinine: cystatin C to the rescue? Evidence, pitfalls and knowledge gaps
    Elliott Van Regemorter, Eléonore Ponlot, Lidvine Boland, Valentine Gillion, Arnaud Devresse · 2025 · European Journal of Internal Medicine
  26. Assessment, prevention, and management of cardiovascular disease risk factors in children with chronic kidney disease, on dialysis and after transplantation: clinical practice recommendations from the European Society for Paediatric Nephrology
    Stella Stabouli, Manish D. Sinha, Fabio Paglialonga, Justine Bacchetta, Julie Bernardor, Dorota Drożdż, Ali Düzova, Charles Joseph Ferro, Alexander D. Lalayiannis, Anette Melk et al. · 2025 · The Lancet Child & Adolescent Health
  27. Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC)
    Benjamin Bouillet, Romain Boulestreau, Victor Aboyans, Sophie Béliard, Franck Boccara, Bertrand Cariou, Sybil Charrière, Philippe Moulin, Bruno L Vergès, René Valéro et al. · 2026 · Archives of cardiovascular diseases
  28. Comparative Effectiveness of Lipid-Lowering Therapies in Increasing High-Density Lipoprotein Cholesterol Levels in Patients with Chronic Kidney Disease
    Mohammad Abdullah Al Zubair Naim, Fridtjof Thomas, Elani Streja, Robert Lowell Davis, Kamyar Kalantar‐Zadeh, Keiichi Sumida, Csaba Pal Kovesdy · 2026 · The Nephron journals/Nephron journals
  29. Prognostic significance and interplay of circulatory PCSK-9–ApoCIII–chemokine axis in type 2 diabetes and its complications: a pilot study in North Indian patients
    Mohd Waiz, Sahir Sultan Alvi, Parvej Ahmad, Bodor H. Bin Sheeha, Paridhi Puri, Irfan Ahmad, Saheem Ahmad, M. Salman Khan · 2026 · The Egyptian Journal of Internal Medicine
  30. Not so "good" cholesterol
    Leonard Kritharides · 2014 · BMJ
  31. Dyslipidemia aterogenna w codziennej praktyce — interdyscyplinarny konsensus polskich ekspertów
    Filip M. Szymański, Krzysztof Jerzy Filipiak, Beata Wożakowska−Kapłon, Jacek Paweł Szaflik, Grzegorz Jan Dzida, Iwona Kurkowska‐Jastrzębska, Krzysztof Narkiewicz, Monika Łazicka-Gałecka, Robert Julian Gil, Janusz Gumprecht · 2017 · Folia Cardiologica
  32. Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study
    Hisato Shima, Manabu Tashiro, Tomoko Inoue, Kazuyoshi Okada, Takuya Okamoto, Seiichiro Wariishi, Toshio Doi, Jun Minakuchi · 2024 · Cureus
  33. Treatment Goals in Diabetic Nephropathy
    Gerald Vervoort · 2018 · Springer eBooks
  34. Lipid metabolism disorders in patients with type 2 diabetes mellitus: focus on hypertriglyceridemia
    Tatiana Yu. Demidova, Ушанова Фатима Омариевна · 2024 · FOCUS Endocrinology
  35. Effects of Pemafibrate on Cardio-Ankle Vascular Index (CAVI) in Patients with Type 2 Diabetes or Ischemic Heart Disease: A 24-Week Observational Study
    Yasuhiro Watanabe, Shoya Nonaka, Shuhei Yamaoka, Shoko Nakamura, Osamu Horikawa, Takashi Yamaguchi, Shuji Sato, Shunsuke Todani, Yuta Sugizaki, Takuro Ito et al. · 2025 · Vascular Health and Risk Management
  36. Evaluation and management of metabolic-associated chronic kidney disease
    Sunita Bavanandan, Narayan Prasad · 2026 · Best Practice & Research Clinical Endocrinology & Metabolism
  37. Importance and Management of Non–High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment
    Richard Charles O’Brien, Lourdes Ella G. Santos, Brian Tomlinson, Zanariah Binti Hussein, Soo Lim, Hapizah Mohd Nawawi, Hean Yee Ong, SILKI Silki, Sidartawan Soegondo, Ta‐Chen Su et al. · 2026 · JACC Asia
  38. Los fibratos en el control del síndrome metabólico
    Carlos Guijarro · 2013 · Hipertensión y Riesgo Vascular
  39. Diabetic Kidney Disease: A Report From an ADA Consensus
    Katherine R. Tuttle, George L. Bakris, Rudolf W. Bilous, Jane L. Chiang, Ian H. de Boer, Irl B. Hirsch, Kamyar Kalantar‐Zadeh, Andrew S. Narva, Sankar Dass Navaneethan, Joshua J. Neumiller et al. · 2014
  40. Diseases of Renal Microcirculation: Diabetic Nephropathy
    Ineke J. Riphagen, Hiddo J.L. Heerspink, Rijk O. B. Gans, Sandrine Gaillard · 2015 · Springer eBooks
  41. Management of Dyslipidemia in Long-Term Dialysis Patients
    Valeria M. Saglimbene, Suetonia C. Palmer, Giovanni FM Strippoli · 2022 · Elsevier eBooks
  42. Hepatocyte Nuclear Factor-1α Increases Fibrinogen Gene Expression in Liver and Plasma Fibrinogen Concentration in Rats with Experimental Chronic Renal Failure
    Elżbieta Sucajtys-Szulc, Alicja Maria Dębska-Ślizień, Boleslaw Rutkowski, Ryszard Milczarek, Marek Szołkiewicz, Julian Świerczyński, Ryszard Tomasz Smolenski · 2023 · International Journal of Molecular Sciences
  43. Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics
    Bilal Bashir, Zohaib Iqbal, Jonathan D. Schofield, Handrean Soran · 2023 · Elsevier eBooks
  44. Newer Therapeutic Strategies to Alter High-Density Lipoprotein Level and Function
    Nicholas A. Bosch, William H. Frishman · 2013 · Cardiology in Review
  45. Verminderung der Progression einer chronischen Niereninsuffizienz
    Daniel Sollinger, Beate Schamberger, Julia Weinmann‐Menke, Jens Lutz · 2016 · Der Nephrologe
  46. Diabetic Kidney Disease: Identification, Prevention, and Treatment
    M. L. Caramori, Peter R Rossing · 2022 · Springer eBooks
  47. Chronic kidney disease related to diabetes in older patients
    Isaac R. Sinay, Felipe Inserra · 2017 · Wiley eBooks
  48. Diabetic Nephropathy
    Sally M. Marshall, Allan Flyvbjerg · 2016 · Wiley eBooks
  49. Effect of fenofibrate and gemfibrozil on kynurenic acid production in rat kidney in vitro: old drugs, new possibilities
    Izabela Natalia Zakrocka, Wojciech Załuska · 2023 · Research Square
  50. How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly
    Faruk Hilmi Turgut, İhsan Üstün, Cumali Gökçe · 2014 · Springer eBooks
  51. Dyslipidemia in Nephrotic Syndrome
    Minso Kim, Howard Trachtman · 2014 · Springer eBooks
  52. Associated factors of different combined albuminuria and estimated glomerular filtration rate stages among patients with type 2 diabetes mellitus
    Yit‐Sheung Yap, Chih-Ming Chien, Yen‐Kuang Tai · 2015 · International Journal of Diabetes in Developing Countries
  53. Srce i krvni Sudovi
    Branko Beleslin, Marina Deljanin, Vladimir Kanjuh, Biljana J Parapid, Vojislav L. Giga, Milica S. Prostran, Lazar Angelkov, Jovan Balinovac, Miroslav Bikicki, Giuseppe Ambrosio et al. · 2013
  54. Fibrates: Risk Benefits and Role in Treating Dyslipidemias
    Min Jun, Vlado Perkovic · 2015 · Contemporary Endocrinology
  55. The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patients
    Fanny Lepeytre, Héloïse Cardinal, Lorraine Fradette, Jacobien C. Verhave, Marc Dorais, Jacques LeLorier, Vincent Pichette, François Madore · 2016 · Clinical Kidney Journal
  56. Fibrates Improved Cholesterol Levels in Patients with Chronic Kidney Disease
    Kirsten E. Fleischmann · 2012 · Journal watch
  57. KDOQI Commentary KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD
    Mark J. Sarnak, Roy D. Bloom, Paul Muntner, Mahboob Rahman, Jeffrey M. Saland, Linda P. Fried · 2014
  58. Los fibratos en el control del síndrome metabólico Fibrates in control of the metabolic syndrome
    Carlos Guijarro · 2013
  59. Chapter 56 – Management of Dyslipidemia in Long-Term Dialysis Patients
    S. Palmer, G. Strippoli · 2017 · Elsevier eBooks
  60. Drugs for Treatment of Dyslipidemia Available in the USA
    Elani Streja, Dan A. Streja · 2019 · Springer eBooks
  61. Defining and reducing the burden of kidney disease
    Thaminda Liyanage · 2018 · The Sydney eScholarship Repository (The University of Sydney)
  62. Lipid-lowering therapy in selected specific groups of patients
    Pavel J. Kraml · 2020 · Medicína pro praxi
  63. Effects of clarified açai (Euterpe oleracea Mart) supplementation on oxidative stress markers in hemodialysis patients: A randomized, controlled pilot study
    Vieira da Silva Martins Isabelle Christine, Christine Isabelle, Rogez Herve, Nascimento Pinheiro Maria Conceicao, Rodrigues Keuri Eleuterio, Matos Macchi Barbarella de, Reis Andrea Dias, Paiva Bruna Regis, de Brito Jessyca Sousa, da Silva Greicielle Santos et al. · 2020 · Journal of Food Science and Nutrition Therapy
  64. Clinical and economic aspects of fibrates
    O. Ya. Mishchenko, К. О. Каlko, V. F. Оstashko, Yu. I. Greshko, P. H. Klepach, Y. I. Honcharuk · 2020 · Clinical pharmacy
  65. Slowing Chronic Kidney Disease Progression
    Pooja Sanghi, Yasmin Ghanshyam Brahmbhatt · 2021 · Springer eBooks
  66. Heart Failure
    Chen Liu, Yugang Dong, Zhi‐Jun Ou, Jing‐Song Ou · 2021 · Springer eBooks
  67. Heart Failure
    Chen Liu, Yugang Dong, Zhi‐Jun Ou, Jing‐Song Ou · 2020 · Springer eBooks
  68. Journal Club
    2013 · Kidney International
  69. Cholesterol: how to measure and how to treat
    Alison Pottle · 2022 · Practice Nursing
  70. Response to Comment on: “Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”
    Devarapalli Ranjani Durga, Nadella Mounika, Pravallika Mudimala, Ramu Adela · 2023 · Clinical Drug Investigation
  71. Paradoxical mortality differential of HDL cholesterol
    Jyotishman Mukhopadhyay, Debayan Mallik, Sughandha Garg · 2023 · Asian Journal of Medical Sciences
  72. Fibrates
    Peter H. Jones, Eliot A. Brinton · 2015 · Elsevier eBooks
  73. CAPÍTULO 3: MANEJO DE LOS LÍPIDOS EN LA ENFERMEDAD RENAL CRÓNICA
    Natalia Nardelli, Pablo Corral, Sergio Giménez, Augusto Lavalle Cobo, Juan Patricio Nogueira, Laura Ester Schreier · 2024 · Revista de la Sociedad Argentina de Diabetes
  74. Case series showing the safety and changes in lipid profiles of hemodialysis patients with hypertriglyceridemia after pemafibrate administration
    Rino Okada, Yasuhiro Onishi, Naoya Kobayashi, Hiroyuki Ishihara, Tomohisa Yokoyama, Tomoyo Mifune, Yoshimasa Sakurabu, Ichiro Nojima, Hiroshi Morinaga, Haruhito Adam Uchida et al. · 2024 · Renal Replacement Therapy
  75. Impact of fatty acid desaturase 1 (FADS1) on chronic kidney disease via very low-density lipoprotein: A drug target–related mediation Mendelian randomization study
    Yongdi Zuo, Lei Chen, Manrong He, Jingxue Du, Wanxin Tang · 2025 · Journal of clinical lipidology
  76. Neue Standards in der Behandlung der primären biliären Cholangitis
    Marius Vögelin, Andreas Emanuel Kremer · 2025 · Schweizer Gastroenterologie
  77. Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Society of Atherosclerosis (NSFA) and the French Society of Cardiology (SFC)
    Benjamin Bouillet, Romain Boulestreau, Victor Aboyans, Sophie Béliard, Franck Boccara, Bertrand Cariou, Sybil Charrière, Philippe Moulin, Bruno L Vergès, René Valéro et al. · 2025 · Annales d Endocrinologie
  78. Current perspectives on lipid management in diabetic kidney disease: Can fibrates offer advantages over statins for renal outcomes?
    Mohammad Reza Chitsazi, Farzad Safari, Elena Malekpour, Seyed Arsham Mirzaei, Mohammad Hossein Shafieyoun, Faraz Golafshan, Hanieh Rouzbahani, Mohadese Nekookhoo, Ali Noursina, Mansour Siavash · 2026 · Journal of Research in Medical Sciences
  79. Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC)
    Benjamin Bouillet, Romain Boulestreau, Victor Aboyans, Sophie Béliard, Franck Boccara, Bertrand Cariou, Sybil Charrière, Philippe Moulin, Bruno L Vergès, René Valéro et al. · 2026 · Diabetes & Metabolism
  80. Design of the Japan Kidney Association-Pemafibrate Intervention for Chronic Kidney Disease patients Study (JKAPI-CKD Study)
    Sho Kinguchi, Kouichi Tamura, Yuichiro Yano, Masaomi Nangaku, Yoshitaka Isaka, Shoichi Maruyama, Hiroshi Kanegae, Hiddo J.L. Heerspink, Naoki Nakagawa, Saori Nishio et al. · 2026 · Clinical Kidney Journal
  81. Lipid-lowering for people with chronic kidney disease: a narrative review
    David J. Tunnicliffe, Rathika Krishnasamy, Giovanni FM Strippoli · 2026 · Drug and Therapeutics Bulletin
  82. Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD
    Mohammad Abdullah Al Zubair Naim, Fridtjof Thomas, Elani Streja, Robert Lowell Davis, Kamyar Kalantar‐Zadeh, Keiichi Sumida, Csaba Pal Kovesdy · 2026 · Clinical Journal of the American Society of Nephrology
  83. Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health
    Ann S. Forrest, Priyanka Majety, Stephanie Mayer, Om P. Ganda · 2026 · Diabetes Obesity and Metabolism
  84. The Role of Angiopoietin-Like Proteins 3 and 4 and Their Target Lipases in CKD: A Drug-Target Mendelian Randomization Study
    Guoyi Yang, David Y. Zhang, Clara J. Fischman, Marina Cuchel, Katalin Suszták, Daniel James Rader · 2026 · American Journal of Kidney Diseases
  85. Cardiovascular Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies in Patients with CKD
    Mohammad Abdullah Al Zubair Naim, Fridtjof Thomas, Elani Streja, Robert Lowell Davis, Kamyar Kalantar‐Zadeh, Keiichi Sumida, Csaba Pal Kovesdy · 2026 · Kidney International Reports
  86. Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome
    Nosratola D. Vaziri · 2015 · Contemporary Endocrinology
  87. Non-statin Therapies for CKD with Dyslipidemia
    István Mucsi · 2014 · Springer eBooks
  88. Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients
    Goto, Hirohito, Iseri, Ken, Hida, Noriko · 2024 · Nephrology Dialysis Transplantation
  89. Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
    Tramontano, Daniele, Bini, Simone, Maiorca, Carlo, Di Costanzo, Alessia, Carosi, Martina, Castellese, Jacopo, Arizaj, Ina, Commodari, Daniela, Covino, Stella, Sansone, Giorgia et al. · 2025 · Drugs